Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

Phosphorylation of HOX11/TLX1 on Threonine-247 during mitosis modulates expression of cyclin B1

Authors: Edwin Chen, Xiaoyong Huang, Yanzhen Zheng, You-Jun Li, Alden Chesney, Yaacov Ben-David, Eric Yang, Margaret R Hough

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

The HOX11/TLX1 (hereafter referred to as HOX11) homeobox gene was originally identified at a t(10;14)(q24;q11) translocation breakpoint, a chromosomal abnormality observed in 5-7% of T cell acute lymphoblastic leukemias (T-ALLs). We previously reported a predisposition to aberrant spindle assembly checkpoint arrest and heightened incidences of chromosome missegregation in HOX11-overexpressing B lymphocytes following exposure to spindle poisons. The purpose of the current study was to evaluate cell cycle specific expression of HOX11.

Results

Cell cycle specific expression studies revealed a phosphorylated form of HOX11 detectable only in the mitotic fraction of cells after treatment with inhibitors to arrest cells at different stages of the cell cycle. Mutational analyses revealed phosphorylation on threonine-247 (Thr247), a conserved amino acid that defines the HOX11 gene family and is integral for the association with DNA binding elements. The effect of HOX11 phosphorylation on its ability to modulate expression of the downstream target, cyclin B1, was tested. A HOX11 mutant in which Thr247 was substituted with glutamic acid (HOX11 T247E), thereby mimicking a constitutively phosphorylated HOX11 isoform, was unable to bind the cyclin B1 promoter or enhance levels of the cyclin B1 protein. Expression of the wildtype HOX11 was associated with accelerated progression through the G2/M phase of the cell cycle, impaired synchronization in prometaphase and reduced apoptosis whereas expression of the HOX11 T247E mutant restored cell cycle kinetics, the spindle checkpoint and apoptosis.

Conclusions

Our results demonstrate that the transcriptional activity of HOX11 is regulated by phosphorylation of Thr247 in a cell cycle-specific manner and that this phosphorylation modulates the expression of the target gene, cyclin B1. Since it is likely that Thr247 phosphorylation regulates DNA binding activity to multiple HOX11 target sequences, it is conceivable that phosphorylation functions to regulate the expression of HOX11 target genes involved in the control of the mitotic spindle checkpoint.
Appendix
Available only for authorised users
Literature
1.
Owens BM, Hawley RG: HOX and non-HOX homeobox genes in leukemic hematopoiesis. Stem Cells. 2002, 20: 364-379. 10.1634/stemcells.20-5-364CrossRefPubMed
2.
Kennedy MA, Gonzalez-Sarmiento R, Kees UR, Lampert F, Dear N, Boehm T, Rabbitts TH: HOX11, a homeobox-containing T-cell oncogene on human chromosome 10q24. Proceedings of the National Academy of Sciences of the United States of America. 1991, 88: 8900-8904. 10.1073/pnas.88.20.8900PubMedCentralCrossRefPubMed
3.
Hatano M, Roberts CW, Minden M, Crist WM, Korsmeyer SJ: Deregulation of a homeobox gene, HOX11, by the t(10;14) in T cell leukemia. Science. 1991, 253: 79-82. 10.1126/science.1676542CrossRefPubMed
4.
Dubé ID, Kamel-Reid S, Yuan CC, Lu M, Wu X, Corpus G, Raimondi SC, Crist WM, Carroll AJ, Minowada J, Baker JB: A novel human homeobox gene lies at the chromosome 10 breakpoint in lymphoid neoplasias with chromosomal translocation t(10;14). Blood. 1991, 78: 2996-3003.PubMed
5.
Ferrando AA, Look AT: Gene expression profiling in T-cell acute lymphoblastic leukemia. Semin Hematol. 2003, 40: 274-280. 10.1016/S0037-1963(03)00195-1CrossRefPubMed
6.
Ferrando AA, Neuberg DS, Dodge RK, Paietta E, Larson RA, Wiernik PH, Rowe JM, Caligiuri MA, Bloomfield CD, Look AT: Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. Lancet. 2004, 363: 535-536. 10.1016/S0140-6736(04)15542-6CrossRefPubMed
7.
Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, Behm FG, Pui CH, Downing JR, Gilliland DG: Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 2002, 1: 75-87. 10.1016/S1535-6108(02)00018-1CrossRefPubMed
8.
Kees UR, Heerema NA, Kumar R, Watt PM, Baker DL, La MK, Uckun FM, Sather HN: Expression of HOX11 in childhood T-lineage acute lymphoblastic leukaemia can occur in the absence of cytogenetic aberration at 10q24: a study from the Children's Cancer Group (CCG). Leukemia. 2003, 17: 887-893. 10.1038/sj.leu.2402892CrossRefPubMed
9.
Bergeron J, Clappier E, Radford I, Buzyn A, Millien C, Soler G, Ballerini P, Thomas X, Soulier J, Dombret H: Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs. Blood. 2007, 110: 2324-2330. 10.1182/blood-2007-04-079988CrossRefPubMed
10.
Asnafi V, Beldjord K, Libura M, Villarese P, Millien C, Ballerini P, Kuhlein E, Lafage-Pochitaloff M, Delabesse E, Bernard O, Macintyre E: Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy. Blood. 2004, 104: 4173-4180. 10.1182/blood-2003-11-3944CrossRefPubMed
11.
Baleydier F, Decouvelaere AV, Bergeron J, Gaulard P, Canioni D, Bertrand Y, Lepretre S, Petit B, Dombret H, Beldjord K: T cell receptor genotyping and HOXA/TLX1 expression define three T lymphoblastic lymphoma subsets which might affect clinical outcome. Clin Cancer Res. 2008, 14: 692-700. 10.1158/1078-0432.CCR-07-1927CrossRefPubMed
12.
Owens BM, Hawley TS, Spain LM, Kerkel KA, Hawley RG: TLX1/HOX11-mediated disruption of primary thymocyte differentiation prior to the CD4+CD8+ double-positive stage. Br J Haematol. 2006, 132: 216-229. 10.1111/j.1365-2141.2005.05850.xPubMedCentralCrossRefPubMed
13.
Greene WK, Ford J, Dixon D, Tilbrook PA, Watt PM, Klinken SP, Kees UR: Enforced expression of HOX11 is associated with an immature phenotype in J2E erythroid cells. Br J Haematol. 2002, 118: 909-917. 10.1046/j.1365-2141.2002.03704.xCrossRefPubMed
14.
Hawley RG, Fong AZ, Lu M, Hawley TS: The HOX11 homeobox-containing gene of human leukemia immortalizes murine hematopoietic precursors. Oncogene. 1994, 9: 1-12.PubMed
15.
Hawley RG, Fong AZ, Reis MD, Zhang N, Lu M, Hawley TS: Transforming function of the HOX11/TCL3 homeobox gene. Cancer Research. 1997, 57: 337-345.PubMed
16.
Hough MR, Reis MD, Singaraja R, Bryce DM, Kamel-Reid S, Dardick I, Breitman RL, Dubé ID: A model for spontaneous B-lineage lymphomas in IgHμ-HOX11 transgenic mice. Proc Natl Acad Sci USA. 1998, 95: 13853-13858. 10.1073/pnas.95.23.13853PubMedCentralCrossRefPubMed
17.
Rosic-Kablar S, Chan K, Reis MD, Dubé ID, Hough MR: Induction of tolerance to immunogenic tumor antigens associated with lymphomagenesis in HOX11 transgenic mice. Proc Natl Acad Sci USA. 2000, 97: 13300-13305. 10.1073/pnas.240221297PubMedCentralCrossRefPubMed
18.
Zhang N, Shen W, Ho AD, Lu M: Three distinct domains in the HOX-11 homeobox oncoprotein are required for optimal transactivation. Oncogene. 1996, 13: 1781-1787.PubMed
19.
Owens BM, Zhu YX, Suen TC, Wang PX, Greenblatt JF, Goss PE, Hawley RG: Specific homeodomain-DNA interactions are required for HOX11-mediated transformation. Blood. 2003, 101: 4966-4974. 10.1182/blood-2002-09-2857CrossRefPubMed
20.
Tang S, Breitman ML: The optimal binding sequence of the Hox11 protein contains a predicted recognition core motif. Nucleic Acids Research. 1995, 23: 1928-1935. 10.1093/nar/23.11.1928PubMedCentralCrossRefPubMed
21.
Greene WK, Bahn S, Masson N, Rabbitts TH: The T-cell oncogenic protein HOX11 activates Aldh1 expression in NIH 3T3 cells but represses its expression in mouse spleen development. Mol Cell Biol. 1998, 18: 7030-7037.PubMedCentralCrossRefPubMed
22.
Masson N, Greene WK, Rabbitts TH: Optimal activation of an endogenous gene by HOX11 requires the NH2- terminal 50 amino acids. Mol Cell Biol. 1998, 18: 3502-3508.PubMedCentralCrossRefPubMed
23.
Allen TD, Zhu YX, Hawley TS, Hawley RG: Tale homeoproteins as hox11-interacting partners in t-cell leukemia. Leuk Lymphoma. 2000, 39: 241-256.CrossRefPubMed
24.
Kawabe T, Muslin AJ, Korsmeyer SJ: HOX11 interacts with protein phosphatases PP2A and PP1 and disrupts a G2/M cell-cycle checkpoint. Nature. 1997, 385: 454-458. 10.1038/385454a0CrossRefPubMed
25.
Riz I, Hawley RG: G1/S transcriptional networks modulated by the HOX11/TLX1 oncogene of T-cell acute lymphoblastic leukemia. Oncogene. 2005, 24: 5561-5575. 10.1038/sj.onc.1208727PubMedCentralCrossRefPubMed
26.
Hoffmann K, Dixon DN, Greene WK, Ford J, Taplin R, Kees UR: A microarray model system identifies potential new target genes of the proto-oncogene HOX11. Genes Chromosomes Cancer. 2004, 41: 309-320. 10.1002/gcc.20104CrossRefPubMed
27.
Dorrell C, Hawley R, Squire J, Dick J: Expression of the HOX11 Oncogene in Primary Primitive Human Hematopoietic Cells Blocks Myeloid Differentiation and Impairs the Response to DNA Damage. Blood. 2003, 102: S399-
28.
Chen E, Kwon YT, Lim MS, Dubé ID, Hough MR: Loss of UBR1 Promotes Aneuploidy and Accelerates B cell Lymphomagenesis in HOX11-Transgenic Mice. Oncogene. 2006, 25: 5752-5763. 10.1038/sj.onc.1209573CrossRefPubMed
29.
Chen E, Lim MS, Rosic-Kablar S, Liu J, Jolicoeur P, Dubé ID, Hough MR: Dysregulated expression of mitotic regulators is associated with B-cell lymphomagenesis in HOX11-transgenic mice. Oncogene. 2006, 25: 2575-2587. 10.1038/sj.onc.1209285CrossRefPubMed
30.
Gillis S, Watson J: Biochemical and biological characterization of lymphocyte regulatory molecules. V. Identification of an interleukin 2-producing human leukemia T cell line. J Exp Med. 1980, 152: 1709-1719. 10.1084/jem.152.6.1709CrossRefPubMed
31.
Muehlbauer PA, Schuler MJ: Detection of numerical chromosomal aberrations by flow cytometry: a novel process for identifying aneugenic agents. Mutat Res. 2005, 585: 156-169.CrossRefPubMed
32.
Kim EA, Noh YT, Ryu MJ, Kim HT, Lee SE, Kim CH, Lee C, Kim YH, Choi CY: Phosphorylation and transactivation of Pax6 by homeodomain-interacting protein kinase 2. J Biol Chem. 2006, 281: 7489-7497. 10.1074/jbc.M507227200CrossRefPubMed
33.
Hjerrild M, Stensballe A, Jensen ON, Gammeltoft S, Rasmussen TE: Protein kinase A phosphorylates serine 267 in the homeodomain of engrailed-2 leading to decreased DNA binding. FEBS Lett. 2004, 568: 55-59. 10.1016/j.febslet.2004.05.009CrossRefPubMed
34.
Pulford K, Lecointe N, Leroy-Viard K, Jones M, Mathieu-Mahul D, Mason DY: Expression of TAL-1 proteins in human tissues. Blood. 1995, 85: 675-684.PubMed
35.
Jaffe L, Ryoo HD, Mann RS: A role for phosphorylation by casein kinase II in modulating Antennapedia activity in Drosophila. Genes Dev. 1997, 11: 1327-1340. 10.1101/gad.11.10.1327CrossRefPubMed
36.
Gay NJ, Poole SJ, Kornberg TB: The Drosophila engrailed protein is phosphorylated by a serine-specific protein kinase. Nucleic Acids Res. 1988, 16: 6637-6647. 10.1093/nar/16.14.6637PubMedCentralCrossRefPubMed
37.
Berry M, Gehring W: Phosphorylation status of the SCR homeodomain determines its functional activity: essential role for protein phosphatase 2A, B'. Embo J. 2000, 19: 2946-2957. 10.1093/emboj/19.12.2946PubMedCentralCrossRefPubMed
38.
Li C, Manley JL: Allosteric regulation of even-skipped repression activity by phosphorylation. Mol Cell. 1999, 3: 77-86. 10.1016/S1097-2765(00)80176-8CrossRefPubMed
39.
Santaguida M, Ding Q, Berube G, Truscott M, Whyte P, Nepveu A: Phosphorylation of the CCAAT displacement protein (CDP)/Cux transcription factor by cyclin A-Cdk1 modulates its DNA binding activity in G(2). J Biol Chem. 2001, 276: 45780-45790. 10.1074/jbc.M107978200CrossRefPubMed
40.
Ford HL, Landesman-Bollag E, Dacwag CS, Stukenberg PT, Pardee AB, Seldin DC: Cell cycle-regulated phosphorylation of the human SIX1 homeodomain protein. J Biol Chem. 2000, 275: 22245-22254. 10.1074/jbc.M002446200CrossRefPubMed
41.
Segil N, Roberts SB, Heintz N: Mitotic phosphorylation of the Oct-1 homeodomain and regulation of Oct-1 DNA binding activity. Science. 1991, 254: 1814-1816. 10.1126/science.1684878CrossRefPubMed
42.
Caelles C, Hennemann H, Karin M: M-phase-specific phosphorylation of the POU transcription factor GHF-1 by a cell cycle-regulated protein kinase inhibits DNA binding. Mol Cell Biol. 1995, 15: 6694-6701.PubMedCentralCrossRefPubMed
43.
Jean A, Gutierrez-Hartmann A, Duval DL: A Pit-1 threonine 220 phosphomimic reduces binding to monomeric DNA sites to inhibit ras and estrogen stimulation of the prolactin gene promoter. Mol Endocrinol. 2010, 24: 91-103. 10.1210/me.2009-0279PubMedCentralCrossRefPubMed
44.
Kasahara H, Izumo S: Identification of the in vivo casein kinase II phosphorylation site within the homeodomain of the cardiac tisue-specifying homeobox gene product Csx/Nkx2.5. Mol Cell Biol. 1999, 19: 526-536.PubMedCentralCrossRefPubMed
45.
Soufi A, Noy P, Buckle M, Sawasdichai A, Gaston K, Jayaraman PS: CK2 phosphorylation of the PRH/Hex homeodomain functions as a reversible switch for DNA binding. Nucleic Acids Res. 2009, 37: 3288-3300. 10.1093/nar/gkp197PubMedCentralCrossRefPubMed
46.
Vijapurkar U, Fischbach N, Shen W, Brandts C, Stokoe D, Lawrence HJ, Largman C: Protein kinase C-mediated phosphorylation of the leukemia-associated HOXA9 protein impairs its DNA binding ability and induces myeloid differentiation. Mol Cell Biol. 2004, 24: 3827-3837. 10.1128/MCB.24.9.3827-3837.2004PubMedCentralCrossRefPubMed
47.
Wang H, Lindsey S, Konieczna I, Bei L, Horvath E, Huang W, Saberwal G, Eklund EA: Constitutively active SHP2 cooperates with HoxA10 overexpression to induce acute myeloid leukemia. J Biol Chem. 2009, 284: 2549-2567. 10.1074/jbc.M804704200PubMedCentralCrossRefPubMed
48.
Lindsey S, Huang W, Wang H, Horvath E, Zhu C, Eklund EA: Activation of SHP2 protein-tyrosine phosphatase increases HoxA10-induced repression of the genes encoding gp91(PHOX) and p67(PHOX). J Biol Chem. 2007, 282: 2237-2249. 10.1074/jbc.M608642200CrossRefPubMed
49.
Lindsey S, Zhu C, Lu YF, Eklund EA: HoxA10 represses transcription of the gene encoding p67phox in phagocytic cells. J Immunol. 2005, 175: 5269-5279.CrossRefPubMed
50.
Eklund EA, Goldenberg I, Lu Y, Andrejic J, Kakar R: SHP1 protein-tyrosine phosphatase regulates HoxA10 DNA binding and transcriptional repression activity in undifferentiated myeloid cells. J Biol Chem. 2002, 277: 36878-36888. 10.1074/jbc.M203917200CrossRefPubMed
51.
Fienberg AA, Nordstedt C, Belting HG, Czernik AJ, Nairn AC, Gandy S, Greengard P, Ruddle FH: Phylogenetically conserved CK-II phosphorylation site of the murine homeodomain protein Hoxb-6. J Exp Zool. 1999, 285: 76-84. 10.1002/(SICI)1097-010X(19990415)285:1<76::AID-JEZ9>3.0.CO;2-KCrossRefPubMed
52.
Yaron Y, McAdara JK, Lynch M, Hughes E, Gasson JC: Identification of novel functional regions important for the activity of HOXB7 in mammalian cells. J Immunol. 2001, 166: 5058-5067.CrossRefPubMed
53.
Bei L, Lu Y, Eklund EA: HOXA9 activates transcription of the gene encoding gp91Phox during myeloid differentiation. J Biol Chem. 2005, 280: 12359-12370. 10.1074/jbc.M408138200CrossRefPubMed
54.
Wang H, Lu Y, Huang W, Papoutsakis ET, Fuhrken P, Eklund EA: HoxA10 activates transcription of the gene encoding mitogen-activated protein kinase phosphatase 2 (Mkp2) in myeloid cells. J Biol Chem. 2007, 282: 16164-16176. 10.1074/jbc.M610556200CrossRefPubMed
55.
Thomas PQ, Brown A, Beddington RS: Hex: a homeobox gene revealing peri-implantation asymmetry in the mouse embryo and an early transient marker of endothelial cell precursors. Development. 1998, 125: 85-94.PubMed
56.
Mack DL, Leibowitz DS, Cooper S, Ramsey H, Broxmeyer HE, Hromas R: Down-regulation of the myeloid homeobox protein Hex is essential for normal T-cell development. Immunology. 2002, 107: 444-451. 10.1046/j.1365-2567.2002.01523.xPubMedCentralCrossRefPubMed
57.
Li J, Shen H, Himmel KL, Dupuy AJ, Largaespada DA, Nakamura T, Shaughnessy JD, Jenkins NA, Copeland NG: Leukaemia disease genes: large-scale cloning and pathway predictions. Nat Genet. 1999, 23: 348-353. 10.1038/15531CrossRefPubMed
58.
George A, Morse HC, Justice MJ: The homeobox gene Hex induces T-cell-derived lymphomas when overexpressed in hematopoietic precursor cells. Oncogene. 2003, 22: 6764-6773. 10.1038/sj.onc.1206822CrossRefPubMed
59.
Desjobert C, Noy P, Swingler T, Williams H, Gaston K, Jayaraman PS: The PRH/Hex repressor protein causes nuclear retention of Groucho/TLE co-repressors. Biochem J. 2009, 417: 121-132. 10.1042/BJ20080872PubMedCentralCrossRefPubMed
60.
Topisirovic I, Kentsis A, Perez JM, Guzman ML, Jordan CT, Borden KL: Eukaryotic translation initiation factor 4E activity is modulated by HOXA9 at multiple levels. Mol Cell Biol. 2005, 25: 1100-1112. 10.1128/MCB.25.3.1100-1112.2005PubMedCentralCrossRefPubMed
61.
Swingler TE, Bess KL, Yao J, Stifani S, Jayaraman PS: The proline-rich homeodomain protein recruits members of the Groucho/Transducin-like enhancer of split protein family to co-repress transcription in hematopoietic cells. J Biol Chem. 2004, 279: 34938-34947. 10.1074/jbc.M404488200CrossRefPubMed
62.
Topisirovic I, Culjkovic B, Cohen N, Perez JM, Skrabanek L, Borden KL: The proline-rich homeodomain protein, PRH, is a tissue-specific inhibitor of eIF4E-dependent cyclin D1 mRNA transport and growth. EMBO J. 2003, 22: 689-703. 10.1093/emboj/cdg069PubMedCentralCrossRefPubMed
63.
Riz I, Lee HJ, Baxter KK, Behnam R, Hawley TS, Hawley RG: Transcriptional activation by TLX1/HOX11 involves Gro/TLE corepressors. Biochem Biophys Res Commun. 2009, 380: 361-365. 10.1016/j.bbrc.2009.01.099PubMedCentralCrossRefPubMed
64.
Topisirovic I, Guzman ML, McConnell MJ, Licht JD, Culjkovic B, Neering SJ, Jordan CT, Borden KL: Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol. 2003, 23: 8992-9002. 10.1128/MCB.23.24.8992-9002.2003PubMedCentralCrossRefPubMed
65.
Chen YJ, Dominguez-Brauer C, Wang Z, Asara JM, Costa RH, Tyner AL, Lau LF, Raychaudhuri P: A conserved phosphorylation site within the forkhead domain of FoxM1B is required for its activation by cyclin-CDK1. J Biol Chem. 2009, 284: 30695-30707. 10.1074/jbc.M109.007997PubMedCentralCrossRefPubMed
66.
Roberts SB, Segil N, Heintz N: Differential phosphorylation of the transcription factor Oct1 during the cell cycle. Science. 1991, 253: 1022-1026. 10.1126/science.1887216CrossRefPubMed
67.
Segil N, Guermah M, Hoffmann A, Roeder RG, Heintz N: Mitotic regulation of TFIID: inhibition of activator-dependent transcription and changes in subcellular localization. Genes Dev. 1996, 10: 2389-2400. 10.1101/gad.10.19.2389CrossRefPubMed
68.
Koehler K, Franz T, Dear TN: Hox11 is required to maintain normal Wt1 mRNA levels in the developing spleen. Dev Dyn. 2000, 218: 201-206. 10.1002/(SICI)1097-0177(200005)218:1<201::AID-DVDY18>3.0.CO;2-RCrossRefPubMed
69.
Brendolan A, Ferretti E, Salsi V, Moses K, Quaggin S, Blasi F, Cleary ML, Selleri L: A Pbx1-dependent genetic and transcriptional network regulates spleen ontogeny. Development. 2005, 132: 3113-3126. 10.1242/dev.01884CrossRefPubMed
70.
Dixon DN, Izon DJ, Dagger S, Callow MJ, Taplin RH, Kees UR, Greene WK: TLX1/HOX11 transcription factor inhibits differentiation and promotes a non-haemopoietic phenotype in murine bone marrow cells. Br J Haematol. 2007, 138: 54-67. 10.1111/j.1365-2141.2007.06626.xCrossRefPubMed
71.
Milech N, Gottardo NG, Ford J, D'Souza D, Greene WK, Kees UR, Watt PM: MEIS proteins as partners of the TLX1/HOX11 oncoprotein. Leuk Res. 2010, 34: 358-363. 10.1016/j.leukres.2009.06.003CrossRefPubMed
72.
Zhang N, Shen W, Hawley RG, Lu M: HOX11 interacts with CTF1 and mediates hematopoietic precursor cell immortalization. Oncogene. 1999, 18: 2273-2279. 10.1038/sj.onc.1202545CrossRefPubMed
73.
Malumbres M, Barbacid M: Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009, 9: 153-166. 10.1038/nrc2602CrossRefPubMed
74.
Viallard JF, Lacombe F, Dupouy M, Ferry H, Belloc F, Reiffers J: Different expression profiles of human cyclin B1 in normal PHA-stimulated T lymphocytes and leukemic T cells. Cytometry. 2000, 39: 117-125. 10.1002/(SICI)1097-0320(20000201)39:2<117::AID-CYTO4>3.0.CO;2-#CrossRefPubMed
75.
Viallard JF, Lacombe F, Dupouy M, Ferry H, Belloc F, Reiffers J: Flow cytometry study of human cyclin B1 and cyclin E expression in leukemic cell lines: cell cycle kinetics and cell localization. Exp Cell Res. 1999, 247: 208-219. 10.1006/excr.1998.4352CrossRefPubMed
76.
Shen M, Feng Y, Gao C, Tao D, Hu J, Reed E, Li QQ, Gong J: Detection of cyclin b1 expression in g(1)-phase cancer cell lines and cancer tissues by postsorting Western blot analysis. Cancer Res. 2004, 64: 1607-1610.CrossRefPubMed
77.
Yasuda M, Takesue F, Inutsuka S, Honda M, Nozoe T, Korenaga D: Overexpression of cyclin B1 in gastric cancer and its clinicopathological significance: an immunohistological study. J Cancer Res Clin Oncol. 2002, 128: 412-416. 10.1007/s00432-002-0359-9CrossRefPubMed
78.
Korenaga D, Takesue F, Yasuda M, Honda M, Nozoe T, Inutsuka S: The relationship between cyclin B1 overexpression and lymph node metastasis in human colorectal cancer. Surgery. 2002, 131: S114-120. 10.1067/msy.2002.119362CrossRefPubMed
79.
Hassan KA, Ang KK, El-Naggar AK, Story MD, Lee JI, Liu D, Hong WK, Mao L: Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res. 2002, 62: 6414-6417.PubMed
80.
Takeno S, Noguchi T, Kikuchi R, Uchida Y, Yokoyama S, Muller W: Prognostic value of cyclin B1 in patients with esophageal squamous cell carcinoma. Cancer. 2002, 94: 2874-2881. 10.1002/cncr.10542CrossRefPubMed
81.
Yoshida T, Tanaka S, Mogi A, Shitara Y, Kuwano H: The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol. 2004, 15: 252-256. 10.1093/annonc/mdh073CrossRefPubMed
82.
Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK, Mao L: Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res. 2000, 60: 4000-4004.PubMed
83.
Chang TH, Schlegel R: SV40 T antigen increases the expression and activities of p34cdc2, cyclin A, and cyclin B prior to immortalization of human diploid fibroblasts. J Cell Biochem. 1996, 60: 161-172. 10.1002/(SICI)1097-4644(19960201)60:2<161::AID-JCB1>3.0.CO;2-VCrossRefPubMed
84.
Kaufmann WK, Schwartz JL, Hurt JC, Byrd LL, Galloway DA, Levedakou E, Paules RS: Inactivation of G2 checkpoint function and chromosomal destabilization are linked in human fibroblasts expressing human papillomavirus type 16 E6. Cell Growth Differ. 1997, 8: 1105-1114.PubMed
Metadata
Title
Phosphorylation of HOX11/TLX1 on Threonine-247 during mitosis modulates expression of cyclin B1
Authors
Edwin Chen
Xiaoyong Huang
Yanzhen Zheng
You-Jun Li
Alden Chesney
Yaacov Ben-David
Eric Yang
Margaret R Hough
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-246

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue

Erratum

Erratum to: Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers

Research

Aberrant WNT/β-catenin signaling in parathyroid carcinoma

Research

A Genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers

Research

Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor

Research

Serum N-glycome biomarker for monitoring development of DENA-induced hepatocellular carcinoma in rat

Research

Cell cycle-dependent regulation of the bi-directional overlapping promoter of human BRCA2/ZAR2 genes in breast cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits